Mirati Therapeutics (MRTX) Misses Q4 EPS by 14c

Mirati Therapeutics (NASDAQ: MRTX) reported Q4 EPS of ($3.51), $0.14 worse than the analyst estimate of ($3.37). Revenue for the quarter came in at $930 thousand versus the consensus estimate of $2.44 million.

For earnings history and earnings-related data on Mirati Therapeutics (MRTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c